SSRI discontinuation syndrome
SSRI discontinuation syndrome, also known as SSRI withdrawal syndrome or SSRI cessation syndrome, is a syndrome that can occur following the interruption, dose reduction, or discontinuation of SSRI (selective serotonin re-uptake inhibitor) or SNRI antidepressant medications. The condition begins following the discontinuation of the drug. It may also occur following a reduction in the dosage of the drug, even though the drug has not been completely discontinued. The time of onset of symptoms depends upon the elimination half-life of the drug and the patient's metabolism. Withdrawal can be broken into two phases- immediate symptoms, occurring within 6 weeks of discontinuation, and less frequently, persistent symptoms that occur months or years after discontinuation.
The particulars of the syndrome, in light of the multitude of prescribed agents, have been disputed. Nonetheless, double-blind placebo controlled trials demonstrate statistically and clinically significant indications of difficulties with the discontinuing of SSRIs.
- 1 Signs and symptoms
- 2 History
- 3 Cause
- 4 Post-SSRI sexual dysfunction
- 5 Diagnosis
- 6 Mechanism
- 7 Prevention and treatment
- 8 Persistent adverse effects
- 9 Discontinuation of SNRIs
- 10 Fluoxetine as an intervention
- 11 Neonatal withdrawal
- 12 See also
- 13 References
- 14 External links
Signs and symptoms
- Interruption, cessation, or reduction of dosage in an SSRI treatment that has lasted four or more weeks.
- Symptoms which:
- interfere with normal social, occupational, or other functioning.
- are not due to another medical condition, drug use, or discontinuation.
- are not due to a relapse of the condition for which the SSRI was originally prescribed.
Symptoms described as "brain zaps," "brain shocks," "brain shivers," "brain pulse-waves," "head shocks," "pulses," "flickers," or "cranial zings" are common withdrawal symptoms experienced during discontinuation (or reduction of dose) of antidepressant drugs. These result from a global downregulation of serotonin receptors in response to increased levels of serotonin in the synaptic cleft, but the specific mechanism through which this creates symptoms is not understood. Common responses to dose reduction or cessation include dizziness, electric shock-like sensations, sweating, nausea, insomnia, tremor, confusion, nightmares, and vertigo. The MedDRA "preferred term" for coding these types of symptoms in adverse drug reaction reports (for use in pharmacovigilance databases such as under the Yellow Card Scheme) is paraesthesia.
In a 1997 survey in north-east England, a "sizable minority" of medical professionals were not confidently aware of the existence of antidepressant withdrawal symptoms. A 2005 review of adverse event reporting showed that descriptions of "electric shocks" from patients on paroxetine had been reported more frequently than some other symptoms.
The first report of withdrawal symptoms occurring after SSRI discontinuation was for fluvoxamine (brand names Luvox (US), Faverin (UK)) in 1992. The Committee on Safety of Medicines in the United Kingdom reported withdrawal symptoms involving paroxetine (Paxil, Seroxat) in 1993, and the American Journal of Psychiatry revealed the same for sertraline (Zoloft, Lustral) the following year.
In 1996, Eli Lilly and Company sponsored a symposium to address the increasing number of reports of patients who had difficult symptoms after going off their antidepressants:
By then it had become clear that drug-company estimates that at most a few percent of those who took antidepressants would have a hard time getting off were far too low. Jerrold Rosenbaum and Maurizio Fava, researchers at Massachusetts General Hospital, found that among people getting off antidepressants, anywhere from 20 percent to 80 percent (depending on the drug) suffered what was being called antidepressant withdrawal (but which, after the symposium, was renamed “discontinuation syndrome”).
— The New York Times, May 6, 2007
The World Health Organization (WHO) continues to track withdrawal syndrome, and notes:
SSRIs are an example of how a conceptual confusion over terminology can affect proper reporting, interpretation and communication of adverse drug reactions related to dependence. To avoid the association with dependence, an increasing number of researchers have used a different term, discontinuation syndrome, instead of withdrawal syndrome. The number of hits for discontinuation syndrome in searches of the international medical literature began to increase, relative to the occurrence of withdrawal syndrome, in 1997 after [the Eli Lilly] symposium on antidepressant discontinuation syndrome held in 1996. In fact, dependence syndrome has been reported to the Uppsala Monitoring Centre for all SSRIs through the same postmarketing surveillance systems, although there are significantly fewer reports of dependence syndrome than of withdrawal syndrome.
— The World Health Organization, WHO Technical Report Series 915, 2003
The same WHO note ranks antidepressants according to withdrawal, with paroxetine having the highest number of withdrawal syndrome reports and fluoxetine the highest number of drug dependence reports; the note concludes, "Three SSRIs are among the 30 highest-ranking drugs in the list of drugs for which drug dependence has ever been reported to the Uppsala Monitoring Centre database; a total of 269 reports had been received as of June 2002 (109 reports for fluoxetine, 91 for paroxetine and 69 for sertraline)."
The cause is the abrupt cessation, or rapid tapering of one of the SSRIs or SNRIs.
- citalopram (Celexa, Cipramil, Celepram, Emocal, Sepram, Seropram)
- escitalopram (Lexapro, Cipralex, Esertia, Esipram)
- fluoxetine (Prozac, Fontex, Seromex, Seronil, Sarafem, Fluctin [EUR])
- paroxetine (Paxil, Seroxat, Pexeva, Aropax, Deroxat, Paroxat)
- sertraline (Zoloft, Lustral, Serlain)
- dapoxetine (Priligy)
- fluvoxamine (Luvox, Fevarin, Favoxil)
- venlafaxine (Effexor, Efexor)
- desvenlafaxine (Pristiq)
- duloxetine (Cymbalta)
- vilazodone (Viibryd)
Post-SSRI sexual dysfunction
Although most SSRIs are widely used and generally considered safe, an abrupt cessation, or rapid tapering of SSRI use may result in a discontinuation syndrome that can mimic serious illness and can be very distressing and intensely uncomfortable. Several pharmacokinetic and pharmacodynamic factors influence the frequency and onset of these symptoms. When allowed to run its course, the syndrome duration is variable (usually one to several weeks) and ranges from mild-moderate intensity in most patients, to extremely distressing in a smaller number of patients who may have side effects for months.
With the lack of a definition based on consensus criteria for the syndrome, a discontinuation panel met in Phoenix, Arizona in 1997 and stated:
"SSRI discontinuation symptoms... may emerge when an SSRI is abruptly discontinued, when doses are missed, and less frequently, during dosage reduction. In addition, the symptoms are not attributable to any other cause and can be reversed when the original agent is reinstituted, or one that is pharmacologically similar is substituted. SSRI discontinuation symptoms, in most cases, may be minimized by slowly tapering antidepressant therapy, but there have been several case reports where symptoms occurred consistently even through repeated attempts to taper therapy. Physical symptoms include problems with balance, gastrointestinal and flu-like symptoms, and sensory and sleep disturbances. Psychological symptoms include anxiety and/or agitation, crying spells, irritability and aggressiveness."
— Journal of Clinical Psychiatry(1997) 5u (7):pp5–10
A 2000 study at the Department of Psychiatry at Dalhousie University in Halifax, Nova Scotia constructed diagnostic criteria for SSRI discontinuation syndrome. These criteria are 2 or more of the following symptoms developing within 1 to 7 days of discontinuation or reduction in dosage of an SSRI after at least 1 month's use, when these symptoms cause clinically significant distress or impairment and are not due to a general medical condition or recurrence of a mental disorder: dizziness, light-headedness, vertigo or feeling faint; shock-like sensations or paresthesia; anxiety; diarrhea; fatigue; gait instability; headache; insomnia; irritability; nausea or emesis; tremor; and visual disturbances.
The exact mechanism of SSRI withdrawal syndrome is unknown, and may be due to a variety of factors. Continuing research on discontinuation/withdrawal syndrome has attributed SSRI withdrawal syndrome to electrophysiological changes in the brain (particularly on the 5-HT receptor), and electrophysiological changes in the body (nerve growth factor) in the absence of the SSRI, as well as dopamine dependency, and an over-excited immune system.
The central nervous system (CNS) adapts to the presence of psychoactive drugs. Such adaptation commonly involves the readjustment of neuroreceptors to compensate for the acute pharmacological action of the medication. Desired drug effects may be mediated by such compensatory changes which may explain the delayed onset of therapeutic effect of antidepressants. This adaptation theory also explains why withdrawal symptoms and signs can occur on the discontinuation of such medications as clearance of drug can occur at a rate faster than the brain can readjust to the absence of medication. Hence, pharmacodynamic and pharmacokinetic factors contribute to the risk of a withdrawal syndrome. Pharmacodynamic factors explain why withdrawal syndromes are often a class issue and why the administration of a drug in the same class often relieves withdrawal symptoms. Formal studies have not characterized the relative risk.
One theory states that SSRI withdrawal syndrome is associated with a rostral anterior cingulate Cho/Cre metabolite ratio decrease that may reflect dynamics of rostral anterior cingulate cortex (ACC) function. The ACC appears to play a role in a wide variety of autonomic functions, such as regulating heart rate and blood pressure, and is vital to cognitive functions, such as reward anticipation, decision-making, empathy, and emotion. Neuroscientists indicate the dorsal anterior cingulate cortex is primarily related to rational cognition while the ventral is more related to emotional cognition.
A separate study demonstrated that changes in regional central blood volume of left prefrontal cortex and left caudate nucleus correlate with the emergence of withdrawal symptoms and increased Hamilton Depression Rating Scale after interruption of paroxetine treatment. The findings supported the hypothesis that brain regions implicated in depression, with extensive serotonergic innervation, would exhibit changes in activity associated with emergence of symptoms following drug discontinuation. Cerebral blood volume maps were obtained via dynamic susceptibility functional magnetic resonance imaging (fMRI).
There is speculation concerning the possibility of a temporary deficiency of synaptic serotonin with abrupt withdrawal of an SSRI. This deficiency is compounded by the fact that down-regulated receptors will remain in their relatively hypoactive state for days to weeks. This is believed to result in antidepressant discontinuation syndrome directly or indirectly via downstream effects on other neurotransmitter systems (e.g., norepinephrine, dopamine, and GABA) implicated in depressive and anxiety disorders.
Prevention and treatment
Patients should be advised of the elimination half-life times of their specific medication, and patients should be aware if changing from a long half-life medication such as fluoxetine (Prozac), to a shorter one, that taking their dose regularly becomes much more important. Patients taking fluoxetine can often miss several doses without noticing any discomfort, but the shorter halflife of other SSRIs such as venlafaxine, paroxetine and duloxetine (ranging approximately 10 hours) means that a single missed dose may cause withdrawal symptoms. When discontinuing an SSRI with a short half-life, switching to a drug with a longer half-life (e.g. fluoxetine or citalopram) and then discontinuing from that can decrease the likelihood and severity of withdrawal syndrome.
Treatment is dependent on the severity of the discontinuation reaction and whether or not further antidepressant treatment is warranted. In cases where further antidepressant treatment is required then the only step required is restarting the antidepressant; this is usually the case following patient noncompliance with the drug. If antidepressants are no longer required, treatment depends on symptom severity. Mild reactions may only require reassurance. Moderate cases may require symptom management. Benzodiazepines may be used for insomnia, although it's very important to note that benzodiazepine withdrawal is known to be severe and long-lived. If symptoms of SSRI discontinuation are severe, or do not respond to symptom management, the antidepressant can be reinstated and then withdrawn more cautiously.
Persistent adverse effects
Most cases of discontinuation syndrome last between one and four weeks but a substantial minority, perhaps up to 15% of users, have persistent withdrawal symptoms evident months after withdrawal. Paroxetine and venlafaxine seem to be particularly difficult to discontinue and prolonged withdrawal syndrome lasting over 18 months have been reported with paroxetine.
Long term withdrawal syndromes are not well studied. One Italian study found that in patients with panic disorder and agoraphobia, 45% exhibited a discontinuation syndrome that disappeared within a month in all but 11%. Symptoms of the discontinuation syndrome include agitation, anxiety, akathisia, panic attacks, irritability, hostility, aggressiveness, worsening of mood, dysphoria, crying spells or mood lability, overactivity or hyperactivity, depersonalization, decreased concentration, slowed thinking, confusion, and memory/concentration difficulties.
Discontinuation of SNRIs
SNRIs affect both reuptake inhibition of serotonin and norepinephrine. The two mostly widely prescribed SNRIs are venlafaxine and duloxetine. To these has been added desvenlafaxine. In addition, the widely used analgesic Tramadol, which is molecularly similar to venlafaxine, has been cited as it has SNRI properties which typically are known to affect patients after 3 months or more use in therapeutic doses of 400 mg per day.
Sudden discontinuation of venlafaxine (brand name Effexor) has a high risk of causing potentially severe withdrawal symptoms. Even missing a single dose can cause symptoms of withdrawal. The high risk of withdrawal symptoms reflects venlafaxine's short half-life as well as its effect as a dual uptake inhibitor. Discontinuations have a tendency to be significantly stronger than the withdrawal effects of other antidepressants including the tricyclic antidepressants, but are similar in nature to those of SSRIs with a short half-life such as paroxetine.
Symptoms of discontinuation are similar to other antidepressants including irritability, restlessness, headache, nausea, fatigue, excessive sweating, dysphoria, tremor, vertigo, irregularities in blood pressure, dizziness, visual and auditory hallucinations, feelings of abdominal distension, and paresthesia. Other non-specific mental symptoms may include impaired concentration, bizarre dreams, delirium, cataplexy, agitation, hostility, and worsening of depressive symptoms. Online help groups consistently mention withdrawal from venlafaxine as triggering dreams of a particularly distressing and hellish quality.
Electric shock sensations have also been reported with many patients describing the symptoms as "brain zaps". It has been suggested the sensations may represent an alteration of neuronal activity in the central nervous system.
Eli Lilly and Company, the manufacturer of brand name duloxetine (Cymbalta) states that a "gradual dose reduction is recommended to avoid discontinuation symptoms." Among these symptoms, there may be "dizziness, headache, nausea, diarrhea, paresthesia, irritability, vomiting, insomnia, anxiety, hyperhidrosis, and fatigue."
Patients should be monitored for these symptoms when discontinuing treatment with Cymbalta. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate.
Fluoxetine as an intervention
Many doctors advise patients who are suffering from SSRI discontinuation syndrome to use fluoxetine as a substitute for their current drug. Substituting fluoxetine in the final stages of SSRI discontinuation, or post discontinuation, provides a rate of reduction of antidepressant which can minimize or eradicate withdrawal symptoms in the patient. Fluoxetine migrates slowly from the brain to the blood. The active metabolite of fluoxetine remains a long time in the brain because it is lipophilic, with a biological half-life of 4 to 8 days (the longest of any SSRI). Therefore the level of the drug in the body falls slowly at a rate to which the brain can adjust when the dosage is reduced. Fluoxetine is also available in a liquid formula, allowing the physician to titrate the drug with greater ease (e.g., with an oral syringe).
In a randomized trial, abrupt interruption of antidepressant therapy for 5–8 days was associated with the emergence of new somatic and psychological symptoms with the highest degree in patients treated with paroxetine and to a lesser degree sertraline, with few symptoms seen with fluoxetine.
- Fluoxetine was indicated to cover serotonergic discontinuation syndromes for cessation of paroxetine associated with withdrawal or discontinuation symptoms.
The U.S. Food and Drug Administration (FDA) issued a warning on July 19, 2006 that nursing mothers on SSRIs must discuss treatment with their physicians.
When taken by pregnant women, selective serotonin reuptake inhibitors (SSRIs) cross the placenta and have the potential to affect newborns. Although SSRIs have not been associated with congenital malformations, some evidence suggests that they are associated with neonatal complications such as neonatal abstinence syndrome (NAS) and persistent pulmonary hypertension (PPH).
SSRI withdrawal syndromes have been documented in neonates. Investigators found that by November 2003, a total of 93 cases of SSRI use associated with either neonatal convulsions or withdrawal syndrome had been reported. Subsequently, the authors of a study published in The Lancet concluded that doctors should avoid or cautiously manage the prescribing of these drugs to pregnant women with psychiatric disorders.
- Psychoactive drug
- Benzodiazepine withdrawal syndrome
- Oliver, J.S.; Burrows, G.D.; Norman, T.R. (September 1999). "Discontinuation Syndromes with Selective Serotonin Re-uptake Inhibitors: Are There Clinically Relevant Differences?". CNS Drugs 12 (3): 171–7. doi:10.2165/00023210-199912030-00001. (subscription required (. ))
- Michelson, D.; Fava, M.; Amsterdam, J. et al. (April 2000). "Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial". Br J Psychiatry 176 (4): 363–8. doi:10.1192/bjp.176.4.363. PMID 10827885.
- Aronson, J. (8 October 2005). "Bottled lightning". BMJ 331 (7520): 824. doi:10.1136/bmj.331.7520.824. (registration required (. ))
- Christmas, M.B. (2005). "'Brain shivers': from chat room to clinic". Psychiatric Bulletin 29 (6): 219–21. doi:10.1192/pb.29.6.219.
- Medawar, C.; Herxheimer, A. (2003/2004). "A comparison of adverse drug reaction reports from professionals and users, relating to risk of dependence and suicidal behaviour with paroxetine" (PDF reprint). International Journal of Risk & Safety in Medicine 16: 5–19.
- MHRA (March–April 2003). "MAIL 136". Retrieved 18 April 2009.
- Young, A.H.; Currie, A. (1997). "Physicians' knowledge of antidepressant withdrawal effects: a survey". J Clin Psychiatry 58 (Suppl 7): 28–30. PMID 9219491.
- Szabadi, E. (1992). "Fluvoxamine withdrawal syndrome". Br J Psychiatry 160 (2): 283–4. doi:10.1192/bjp.160.2.283b. PMID 1540778.
- Gelenberg, A.J., ed. (1993). "Postmarketing watch: paroxetine in the UK". Biol Ther Psychiatry 16: 25–8.
- Louie, A.K.; Lannon, R.A.; Ajari, L.J. (1994). "Withdrawal reaction after sertraline discontinuation". Am J Psychiatry 151 (3): 450–1. PMID 8109661.
- Stutz, Bruce (2007-05-06). "Self-Nonmedication". New York Times. Retrieved 2010-05-24.
- World Health Organization (2003). WHO EXPERT COMMITTEE ON DRUG DEPENDENCE – Thirty-third Report / WHO Technical Report Series 915 (Report). World Health Organization. http://apps.who.int/medicinedocs/en/d/Js4896e/9.html.
- Bahrick, A.S. (2006). "Post SSRI Sexual Dysfunction" (PDF). Tablet (American Society for the Advancement of Pharmacotherapy) 7 (3): 2–10.
- Schatzberg, A.F.; Haddad, P.; Kaplan, E.M.; Lejoyeux, M.; Rosenbaum, J.F.; Young, A.H.; Zajecka, J. (1997). "Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. Discontinuation Consensus panel". J Clin Psychiatry 5u (7): 5–10. PMID 9219487.
- Black, K.; Shea, C.; Dursun, S.; Kutcher, S. (2000). "Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria". J Psychiatry Neurosci 25 (3): 255–61. PMC 1407715. PMID 10863885.
- Kaufman, M.J.; Henry, M.E.; Frederick, B.; Hennen, J.; Villafuerte, R.A.; Stoddard, E.P. et al. (2003). "Selective serotonin reuptake inhibitor discontinuation syndrome is associated with a rostral anterior cingulate choline metabolite decrease: a proton magnetic resonance spectroscopic imaging study". Biol Psychiatry 54 (5): 534–9. doi:10.1016/S0006-3223(02)01828-0. PMID 12946882.
- Damsa, C.; Bumb, A.; Bianchi-Demicheli, F. et al. (August 2004). ""Dopamine-dependent" side effects of selective serotonin reuptake inhibitors: a clinical review". J Clin Psychiatry 65 (8): 1064–8. doi:10.4088/JCP.v65n0806. PMID 15323590.
- Haddad, P.M.; Anderson, I.M. (2007). "Recognising and managing antidepressant discontinuation symptoms". Advances in Psychiatric Treatment 13 (6): 447. doi:10.1192/apt.bp.105.001966.
- Haddad, P. (2001). "Antidepressant discontinuation syndromes". Drug Saf 24 (3): 183–97. doi:10.2165/00002018-200124030-00003. PMID 11347722.
- Fava, G.A.; Bernardi, M.; Tomba, E.; Rafanelli, C. (December 2007). "Effects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia". Int. J. Neuropsychopharmacology 10 (6): 835–838. doi:10.1017/S1461145706007462. PMID 17224089.
- Tamam, L.; Ozpoyraz, N. (January–February 2002). "Selective Serotonin Reuptake Inhibitor Discontinuation Syndrome: A Review". Advances in Therapy 19 (1): 17–26. doi:10.1007/BF02850015. PMID 12008858. Retrieved 28 November 2012.
- Fava G.A.; Bernardi, M.; Tomba, E.; Rafanelli, C. (December 2007). "Effects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia". Int. J. Neuropsychopharmacol. 10 (6): 835–8. doi:10.1017/S1461145706007462. PMID 17224089.
- Fava, M.; Mulroy, R.; Alpert, J.; Nierenberg, A.; Rosenbaum, J. (1997). "Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine". Am J Psychiatry 154 (12): 1760–2. PMID 9396960.
- Parker, G.; Blennerhassett, J. (1998). "Withdrawal reactions associated with venlafaxine". Aust N Z J Psychiatry 32 (2): 291–4. doi:10.3109/00048679809062742. PMID 9588310.
- Baboolal, N. (2004). "Venlafaxine withdrawal syndrome: report of seven cases in Trinidad". J Clin Psychopharmacol 24 (2): 229–31. doi:10.1097/01.jcp.0000117427.05703.f2. PMID 15206672.
- van Noorden, M.; Vergouwen, A.; Koerselman, G. (2002). "[Delirium during withdrawal of venlafaxine]". Ned Tijdschr Geneeskd 146 (26): 1236–7. PMID 12132141.
- Nissen, C.; Feige, B.; Nofzinger, E.; Riemann, D.; Berger, M.; Voderholzer, U. (2005). "Transient narcolepsy-cataplexy syndrome after discontinuation of the antidepressant venlafaxine". J Sleep Res 14 (2): 207–8. doi:10.1111/j.1365-2869.2005.00447.x. PMID 15910521.
- Reeves, R.; Mack, J.; Beddingfield, J. (2003). "Shock-like sensations during venlafaxine withdrawal". Pharmacotherapy 23 (5): 678–81. doi:10.1592/phco.23.5.678.32198. PMID 12741444.
- "CYMBALTA (duloxetine hydrochloride) capsule, delayed release". National Institutes of Health, Health & Human Services. July 2013. Retrieved 11 December 2013.
- Cymbalta patient information sheet. Indianapolis, IN: Eli Lilly Pharmaceuticals; July 2006
- Benazzi, F. (1998). "SSRI discontinuation syndrome treated with fluoxetine". Int J Geriatr Psychiatry 13 (6): 421–2. doi:10.1002/(SICI)1099-1166(199806)13:6<421::AID-GPS774>3.0.CO;2-Y. PMID 9658279.
- Rosenbaum, J.F.; Fava, M.; Hoog, S.L.; Ashcroft, R.C.; Krebs, W.B. (1998). "Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial". Biol Psychiatry 44 (2): 77–87. doi:10.1016/S0006-3223(98)00126-7. PMID 9646889.
- Benazzi, F. (April 1999). "Fluoxetine for Clomipramine Withdrawal Symptoms". Am J Psychiatry 156 (4): 661.
- Green B. (2003). "Focus on paroxetine". Curr Med Res Opin 19 (1): 13–21. doi:10.1185/030079902125001353. PMID 12661775.
- "Anti-depressants used during pregnancy linked to neonatal withdrawal syndrome". Medical News Today. Lancet. February 5, 2005.
- "Antidepressant Discontinuation Syndrome". American Family Physician. August 1, 2006.
- "Trouble in Prozac". Fortune Magazine. November 2005.
- Healy, David. "Dependence on Antidepressants & Halting SSRI-PROTOCOL FOR THE WITHDRAWAL OF SSRI ANTIDEPRESSANTS".
- Stutz, Bruce (May 6, 2007). "Self-Nonmedication". New York Times Magazine.
- Glenmullen, Joseph (2000). "Ch. 1". Prozac Backlash. ISBN 0-684-86001-5.